EGFR and non-small cell lung carcinoma: Tong et al. (2019) showed that PTK2 inhibitors and EGFR-TKI restored EGFR-TKI sensitivity in EGFR-TKI-resistant NSCLC. This suggests that PTK2 inhibitors play an important role in patients with acquired EGFR-TKI resistance. There are four classical pathways of MAPK, and these signaling pathways are closely associated with the development of several cancer species (Hargadon, 2023; Imperial et al., 2019).